Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022 - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

China ,Wanzhen ,Jiangsu ,Taiwan ,United States ,Hong Kong ,Macau ,Suzhou ,Chinese ,American ,Innovent Biologics ,Adimab Incyte ,Yujie Zhou ,Eli Lilly ,American Cardiology Association Annual Congress ,Prnewswire Innovent Biologics Inc ,China Cardiovascular Health ,Capital Medical University ,Md Anderson Cancer Center ,American College Of Cardiology Annual Congress ,Company Codes ,Incyte Corporation ,American College ,Cardiology Annual Congress ,Vice President ,Anzhen Hospital ,Lei Qian ,Cardiovascular Health ,Disease Report ,Three Registration Clinical Studies ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,Resume ,Careers ,Nnovent Releases Results Ofa Phase 3 Clinical Study Of Ibi306 Pcsk 9 Inhibitor In Chinese Patients With Heterozygous Familial Hypercholesterolemia At The American College Cardiology Annual Congress 2022 ,Iospace ,Advice ,